A bispecific antibody for multiple myeloma
Linvoseltamab
A hospital-given antibody that brings immune cells together with myeloma cells to help destroy them.
What is Linvoseltamab?
Linvoseltamab is a specialist antibody treatment for multiple myeloma, a cancer of certain blood cells, used when the disease has come back or stopped responding to earlier treatments. It is a bispecific antibody: one part grabs a marker (BCMA) on the myeloma cells and the other part grabs the body's own T-cells, bringing them together so the immune cells destroy the cancer. It is given as an injection in hospital, starting with smaller step-up doses. The most important risks are cytokine release syndrome (a strong immune reaction), effects on the nervous system and serious infections, so it needs close hospital monitoring.
Education and reference only. This is a plain-language guide to Linvoseltamab — it deliberately contains no doses. Doses depend on the person, the brand and the reason for treatment, and belong with your prescriber. Always check the BNF, the product labelling (SmPC) and follow medical advice.
What it is
Linvoseltamab is a medicine used to treat multiple myeloma, a cancer of plasma cells in the bone marrow, in people whose disease has returned or no longer responds to several earlier treatments. It is a bispecific antibody, meaning it is designed to attach to two different targets at once: a protein called BCMA on the surface of myeloma cells, and a protein called CD3 on the body's T-cells. It is given by injection under the care of a specialist team, usually starting in hospital with gradually increasing step-up doses and close monitoring.
How it works
Linvoseltamab works by acting as a bridge between the cancer and the immune system. One arm of the antibody locks onto BCMA, a marker found on myeloma cells, while the other arm locks onto CD3 on T-cells, which are part of the body's natural defences. By holding the two cell types close together, it directs the T-cells to attack and kill the myeloma cells. Because activating the immune system in this way can cause a strong reaction, treatment is started with smaller step-up doses and given with close monitoring, building up to the full dose once it is tolerated.
Company & origin
Originated / developed by: Specialist manufacturer.
A specialist hospital-given antibody treatment used for multiple myeloma that has come back or stopped responding to other treatments.
Practical use
How to take Linvoseltamab
General, dose-free guidance — always follow your prescriber's and the leaflet's specific instructions.
- Have it as an injection given by your specialist team, with the first step-up doses usually in hospital.
- Stay for monitoring around the early doses, as serious reactions are most likely then.
- Report fever, dizziness, breathlessness, confusion or difficulty speaking straight away, at any time.
- Carry your patient alert card and show it to any healthcare professional you see.
- Take any preventive anti-infection medicines as prescribed and attend all your monitoring appointments.
Weighing it up
Advantages & disadvantages of Linvoseltamab
Advantages
- Offers a treatment option for multiple myeloma that has come back or stopped responding to other treatments.
- Uses the body's own T-cells to target and destroy the cancer cells.
- Given on a set schedule with step-up dosing designed to reduce early reactions.
Disadvantages
- Can cause cytokine release syndrome, a strong immune reaction needing hospital monitoring.
- Can affect the nervous system, causing problems such as confusion or difficulty speaking.
- Lowers the body's defences, so serious infections are an important risk.
Practical use
Good to know
The most important things to understand are the main risks and why treatment starts in hospital. Cytokine release syndrome, a strong immune reaction that can cause fever, low blood pressure and breathing problems, is most likely in the early doses, which is why treatment begins with smaller step-up doses and close monitoring. Effects on the nervous system, such as confusion, headache, difficulty speaking or tremor, can also occur and must be reported at once. Because the treatment lowers the body's defences, serious infections are a real risk, so any fever or sign of infection needs urgent attention. People are usually given a patient alert card, told what symptoms to watch for, and monitored closely, especially around each new dose; preventive medicines against infection are often used.
Who should not take it / use with caution
- People who have had a serious allergic reaction to linvoseltamab should not use it.
- It is used with great caution in people with an active serious infection, which is usually treated first.
- It is not recommended in pregnancy, and effective contraception is advised.
- It should only be used in specialist centres able to manage cytokine release syndrome and monitor closely.
Monitoring
- Close monitoring around each early dose for cytokine release syndrome and nervous-system effects.
- Watching for signs of infection, with regular blood-count checks.
- Reviewing how well the myeloma is responding to treatment over time.
Side effects
- Cytokine release syndrome, with fever, chills, low blood pressure or breathing problems, mainly around early doses.
- Nervous-system effects such as headache, confusion, tremor or difficulty speaking.
- Serious infections, because the body's defences are lowered.
- Low blood counts, tiredness and reactions around the time of the injection.
Key interactions
- Vaccines, especially live vaccines, may not be suitable around treatment, so check with your team first.
- Tell your team about all medicines, as some may add to the risk of infection or other effects.
- It is given as part of a carefully planned specialist programme with supportive medicines.
Available as: A solution for injection, given by a specialist team.
Answers
Linvoseltamab: frequently asked questions
What is linvoseltamab used for?
It is used to treat multiple myeloma that has come back or stopped responding to earlier treatments, by bringing the body's T-cells together with the cancer cells.
Why does treatment start with smaller doses?
Starting with step-up doses and close monitoring lowers the risk of cytokine release syndrome, a strong immune reaction that is most likely with the early doses.
What is cytokine release syndrome?
It is a strong immune reaction that can cause fever, chills, low blood pressure and breathing problems; it needs to be recognised and treated quickly, which is why monitoring is so important.
Why am I more likely to get infections?
The treatment lowers the body's natural defences, so serious infections are a real risk; report any fever or sign of infection urgently and take any preventive medicines you are given.
Why do I have a patient alert card?
The card tells other healthcare professionals you are on this treatment so they can act quickly if you develop a reaction, nervous-system symptoms or an infection.
Authoritative sources
- BNF
- NICE CKS
Building a medicines information resource?
We create evidence-led, dose-free drug and formulary references for teams.